Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IRONNASDAQ:RLAYNASDAQ:SDGRNASDAQ:TVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIRONDisc Medicine$42.17+2.9%$49.74$25.64▼$68.73$1.46B0.77347,470 shs347,423 shsRLAYRelay Therapeutics$2.69+3.1%$3.13$1.78▼$10.72$456.01M1.71.97 million shs1.63 million shsSDGRSchrödinger$25.75+2.1%$21.99$16.60▼$28.47$1.88B1.77823,642 shs1.14 million shsTVTXTravere Therapeutics$14.92+2.4%$19.06$5.12▼$25.29$1.32B0.841.52 million shs1.10 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIRONDisc Medicine+2.85%+19.70%-20.18%-27.59%+39.27%RLAYRelay Therapeutics+3.07%+21.17%-18.24%-39.69%-56.68%SDGRSchrödinger+2.14%+33.98%+12.45%+35.53%+2.84%TVTXTravere Therapeutics+2.40%+10.60%-24.80%-18.78%+149.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIRONDisc Medicine2.6316 of 5 stars4.51.00.00.02.22.50.0RLAYRelay Therapeutics2.7337 of 5 stars3.43.00.00.02.72.50.6SDGRSchrödinger2.5316 of 5 stars3.51.00.00.03.72.50.6TVTXTravere Therapeutics2.6085 of 5 stars4.51.00.00.02.80.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIRONDisc Medicine 3.09Buy$93.80122.43% UpsideRLAYRelay Therapeutics 2.82Moderate Buy$18.36582.66% UpsideSDGRSchrödinger 3.00Buy$33.0028.16% UpsideTVTXTravere Therapeutics 2.93Moderate Buy$32.08114.99% UpsideCurrent Analyst Ratings BreakdownLatest RLAY, IRON, TVTX, and SDGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025RLAYRelay TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$4.004/16/2025SDGRSchrödingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $32.004/14/2025TVTXTravere TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$47.00 ➝ $47.004/11/2025TVTXTravere TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform4/10/2025TVTXTravere TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$45.00 ➝ $47.004/3/2025TVTXTravere TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight4/1/2025TVTXTravere TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$29.00 ➝ $31.003/18/2025IRONDisc MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$99.00 ➝ $132.003/7/2025IRONDisc MedicineMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$85.003/7/2025RLAYRelay TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/3/2025IRONDisc MedicineScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$73.00 ➝ $75.00(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIRONDisc MedicineN/AN/AN/AN/A$14.17 per shareN/ARLAYRelay Therapeutics$10.01M45.57N/AN/A$5.90 per share0.46SDGRSchrödinger$207.54M9.06$0.69 per share37.42$7.60 per share3.39TVTXTravere Therapeutics$233.18M5.68N/AN/A$2.67 per share5.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIRONDisc Medicine-$76.43M-$3.99N/AN/AN/AN/A-25.24%-23.96%5/8/2025 (Estimated)RLAYRelay Therapeutics-$341.97M-$2.39N/AN/AN/AN/A-45.75%-40.75%5/1/2025 (Estimated)SDGRSchrödinger$40.72M-$2.57N/AN/AN/A-91.84%-35.77%-24.51%4/29/2025 (Estimated)TVTXTravere Therapeutics-$111.40M-$4.10N/AN/AN/A-137.90%-1,636.87%-55.95%5/5/2025 (Estimated)Latest RLAY, IRON, TVTX, and SDGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025IRONDisc Medicine-$0.99N/AN/AN/AN/AN/A5/7/2025Q1 2025SDGRSchrödinger-$0.81N/AN/AN/A$54.60 millionN/A5/5/2025Q1 2025TVTXTravere Therapeutics-$0.54N/AN/AN/A$77.44 millionN/A5/1/2025Q1 2025RLAYRelay Therapeutics-$0.51N/AN/AN/A$0.01 millionN/A2/27/2025Q4 2024IRONDisc Medicine-$1.06-$0.98+$0.08-$0.98N/AN/A2/26/2025Q4 2024RLAYRelay Therapeutics-$0.57-$0.45+$0.12-$0.45$5.53 millionN/A2/26/2025Q4 2024SDGRSchrödinger-$0.35-$0.55-$0.20-$0.55$83.20 million$88.32 million2/20/2025Q4 2024TVTXTravere Therapeutics-$0.58-$0.73-$0.15-$0.73$72.38 million$74.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIRONDisc MedicineN/AN/AN/AN/AN/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/ASDGRSchrödingerN/AN/AN/AN/AN/ATVTXTravere TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIRONDisc MedicineN/A19.3619.36RLAYRelay TherapeuticsN/A18.4218.42SDGRSchrödingerN/A4.114.11TVTXTravere Therapeutics24.961.711.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIRONDisc Medicine83.70%RLAYRelay Therapeutics96.98%SDGRSchrödinger79.05%TVTXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipIRONDisc Medicine4.24%RLAYRelay Therapeutics4.32%SDGRSchrödinger8.60%TVTXTravere Therapeutics3.75%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIRONDisc Medicine3034.57 million28.50 millionNot OptionableRLAYRelay Therapeutics330169.52 million160.15 millionOptionableSDGRSchrödinger79073.04 million66.59 millionOptionableTVTXTravere Therapeutics46088.77 million75.12 millionOptionableRLAY, IRON, TVTX, and SDGR HeadlinesRecent News About These CompaniesWalleye Capital LLC Sells 61,223 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)April 18 at 5:18 AM | marketbeat.comGuggenheim Reiterates "Buy" Rating for Travere Therapeutics (NASDAQ:TVTX)April 16 at 10:11 AM | marketbeat.comWellington Management Group LLP Makes New $583,000 Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX)April 16 at 3:28 AM | marketbeat.comGuggenheim Reiterates Buy Rating for Travere Therapeutics (NASDAQ:TVTX)April 15 at 1:59 AM | americanbankingnews.com111,158 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Acquired by F M Investments LLCApril 14, 2025 | marketbeat.comNorges Bank Takes $1.24 Million Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)April 14, 2025 | marketbeat.comRenaissance Technologies LLC Purchases 534,500 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)April 13, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Price Target Raised to $47.00April 13, 2025 | americanbankingnews.comFederated Hermes Inc. Acquires 44,500 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)April 12, 2025 | marketbeat.comScotiabank Remains a Buy on Travere Therapeutics (TVTX)April 11, 2025 | markets.businessinsider.comTravere Therapeutics (NASDAQ:TVTX) Shares Gap Down - Time to Sell?April 11, 2025 | marketbeat.comVanguard Group Inc. Sells 159,985 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)April 10, 2025 | marketbeat.comTravere Therapeutics (TVTX) Receives a Buy from Wells FargoApril 10, 2025 | markets.businessinsider.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Rating of "Moderate Buy" by AnalystsApril 10, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Trexquant Investment LPApril 7, 2025 | marketbeat.comSchroder Investment Management Group Sells 260,199 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)April 6, 2025 | marketbeat.comCantor Fitzgerald Reaffirms Overweight Rating for Travere Therapeutics (NASDAQ:TVTX)April 5, 2025 | marketbeat.comTravere Therapeutics (TVTX) Receives a Buy from GuggenheimApril 5, 2025 | markets.businessinsider.comNovartis Has A Slight Edge On Travere — Why Analysts Aren't WorriedApril 3, 2025 | msn.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Stock Position Lessened by Pictet Asset Management Holding SAApril 3, 2025 | marketbeat.comThe Analyst Verdict: Travere Therapeutics In The Eyes Of 7 ExpertsApril 3, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?Can SoundHound AI Double? What the Fundamentals and Deals RevealBy Gabriel Osorio-Mazilli | March 25, 2025View Can SoundHound AI Double? What the Fundamentals and Deals RevealCrowdStrike Stock is a Buy as Cyberthreat Environment ExpandsBy Chris Markoch | April 15, 2025View CrowdStrike Stock is a Buy as Cyberthreat Environment Expands3 Energy Stock Winners Even as Oil Prices PlungeBy Chris Markoch | April 11, 2025View 3 Energy Stock Winners Even as Oil Prices PlungeCoca-Cola Stock Looks Refreshing After the Relief Rally By Chris Markoch | April 13, 2025View Coca-Cola Stock Looks Refreshing After the Relief Rally RLAY, IRON, TVTX, and SDGR Company DescriptionsDisc Medicine NASDAQ:IRON$42.17 +1.17 (+2.85%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$42.17 0.00 (0.00%) As of 04/17/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.Relay Therapeutics NASDAQ:RLAY$2.69 +0.08 (+3.07%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$2.68 -0.02 (-0.56%) As of 04/17/2025 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Schrödinger NASDAQ:SDGR$25.75 +0.54 (+2.14%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$25.60 -0.15 (-0.56%) As of 04/17/2025 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Travere Therapeutics NASDAQ:TVTX$14.92 +0.35 (+2.40%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$14.92 -0.01 (-0.03%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation Unveils NYC Network Ahead of Key Earnings Report Joby Aviation Stock Presents an Opportunity in the Turbulence Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Tariff-Resistant Kinder Morgan Is a Good Buy in 2025 Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks Tariff-Resistant Abbott Laboratories on Track for New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
